Inadequate planning and reporting of adjudication committees in clinical trials: Recommendation proposal

Journal of Clinical Epidemiology

Volumn 62, Issue 7, 2009, Pages 695-702

  Dechartres, Agnes ^a,b,c   Boutron, Isabelle ^a,b,c   Roy, Carine ^a,c   Ravaud, Philippe ^a,b,c  

^a INSERM   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c BICHAT HOSPITAL   (France)

Author keywords

Adjudication committee; Classification bias; Clinical event committee; Endpoint committee; Randomized controlled trials; Recommendations

Indexed keywords

CLASSIFICATION; MEDICAL LITERATURE; METHODOLOGY; PLANNING; PRIORITY JOURNAL; PUBLICATION; RANDOMIZED CONTROLLED TRIAL; REVIEW; RISK FACTOR;

CLINICAL TRIALS DATA MONITORING COMMITTEES; HUMANS; JOURNAL IMPACT FACTOR; OUTCOME ASSESSMENT (HEALTH CARE); RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH DESIGN;

EID: 67349170300     PISSN: 08954356     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jclinepi.2008.09.011     Document Type: Review

References (32)

1. Mahaffey K.W., Roe M.T., Dyke C.K., Newby L.K., Kleiman N.S., Connolly P., et al. Misreporting of myocardial infarction end points: results of adjudication by a central clinical events committee in the PARAGON-B trial. Second platelet IIb/IIIa antagonist for the Reduction of Acute Coronary Syndrome Events in a Global Organization Network Trial. Am Heart J 143 (2002) 242-248
2. U.S. Food and Drug Administration. Guidance for clinical trial sponsors on the establishment and operation of clinical trial data monitoring committees. Available at (2001). http://www.fda.gov/CBER/gdlns/clindatmon.pdf
3. European Medicines Agency. Committee for Medicinal Products for Human Use (CHMP). Available at (2005). http://www.emea.europa.eu/pdfs/human/ewp/587203en.pdf
4. Ives D.G., Fitzpatrick A.L., Bild D.E., Psaty B.M., Kuller L.H., Crowley P.M., et al. Surveillance and ascertainment of cardiovascular events. The Cardiovascular Health Study. Ann Epidemiol 5 (1995 Jul) 278-285
5. Ferguson J.J., Califf R.M., Antman E.M., Cohen M., Grines C.L., Goodman S., et al. Enoxaparin vs unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY randomized trial. JAMA 292 (2004) 45-54
6. Naslund U., Grip L., Fischer-Hansen J., Gundersen T., Lehto S., and Wallentin L. The impact of an end-point committee in a large multicentre, randomized, placebo-controlled clinical trial: results with and without the end-point committee's final decision on end-points. Eur Heart J 20 (1999 May) 771-777
7. Mahaffey K.W., Harrington R.A., Akkerhuis M., Kleiman N.S., Berdan L.G., Crenshaw B.S., et al. Disagreements between central clinical events committee and site investigator assessments of myocardial infarction endpoints in an international clinical trial: review of the PURSUIT study. Curr Control Trials Cardiovasc Med 2 (2001) 187-194
8. Mahaffey K.W., Harrington R.A., Akkerhuis M., Kleiman N.S., Berdan L.G., Crenshaw B.S., et al. Systematic adjudication of myocardial infarction end-points in an international clinical trial. Curr Control Trials Cardiovasc Med 2 (2001) 180-186
9. Lee K.P., Schotland M., Bacchetti P., and Bero L.A. Association of journal quality indicators with methodological quality of clinical research articles. JAMA 287 (2002) 2805-2808
10. Mills E.J., Wu P., Gagnier J., and Devereaux P.J. The quality of randomized trial reporting in leading medical journals since the revised CONSORT statement. Contemp Clin Trials 26 (2005 Aug) 480-487
11. Mills E., Wu P., Gagnier J., Heels-Ansdell D., and Montori V.M. An analysis of general medical and specialist journals that endorse CONSORT found that reporting was not enforced consistently. J Clin Epidemiol 58 (2005) 662-667
12. Boutron I., Estellat C., Guittet L., Dechartres A., Sackett D.L., Hrobjartsson A., et al. Methods of blinding in reports of randomized controlled trials assessing pharmacologic treatments: a systematic review reporting methods of blinding in randomized trials assessing nonpharmacological treatments. PLoS Med 3 (2006) e425
13. Boutron I., Guittet L., Estellat C., Moher D., Hrobjartsson A., and Ravaud P. Reporting methods of blinding in randomized trials assessing nonpharmacological treatments. PLoS Med 4 (2007) e61
14. Boutron I., Tubach F., Giraudeau B., and Ravaud P. Blinding was judged more difficult to achieve and maintain in nonpharmacologic than pharmacologic trials. J Clin Epidemiol 57 (2004) 543-550
15. Devereaux P.J., Bhandari M., Montori V.M., Manns B.J., Ghall W.A., and Guyatt G.H. Double blind, you have been voted off the island!. Evid Based Ment Health 5 (2002) 36-37
16. Devereaux P.J., Manns B.J., Ghali W.A., Quan H., Lacchetti C., Montori V.M., et al. Physician interpretations and textbook definitions of blinding terminology in randomized controlled trials. JAMA 285 (2001) 2000-2003
17. Montori V.M., Bhandari M., Devereaux P.J., Manns B.J., Ghali W.A., and Guyatt G.H. In the dark: the reporting of blinding status in randomized controlled trials. J Clin Epidemiol 55 (2002 Aug) 787-790
18. Walter S.D., Cook D.J., Guyatt G.H., King D., and Troyan S. Outcome assessment for clinical trials: how many adjudicators do we need? Canadian Lung Oncology Group. Control Clin Trials 18 (1997) 27-42
19. Schnitzer T.J., Burmester G.R., Mysler E., Hochberg M.C., Doherty M., Ehrsam E., et al. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomised controlled trial. Lancet 364 (2004) 665-674
20. Mitchell L.G., Andrew M., Hanna K., Abshire T., Halton J., Anderson R., et al. A prospective cohort study determining the prevalence of thrombotic events in children with acute lymphoblastic leukemia and a central venous line who are treated with L-asparaginase: results of the prophylactic antithrombin replacement in kids with acute lymphoblastic leukemia treated with asparaginase (PARKAA) study. Cancer 97 (2003) 508-516
21. Dormandy J.A., Charbonnel B., Eckland D.J., Erdmann E., Massi-Benedetti M., Moules I.K., et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 366 (2005) 1279-1289
22. Cuenca-Estrella M., Moore C.B., Barchiesi F., Bille J., Chryssanthou E., Denning D.W., et al. Multicenter evaluation of the reproducibility of the proposed antifungal susceptibility testing method for fermentative yeasts of the antifungal susceptibility testing subcommittee of the European committee on antimicrobial susceptibility testing (AFST-EUCAST). Clin Microbiol Infect 9 (2003) 467-474
23. Petersen J.L., Haque G., Hellkamp A.S., Flaker G.C., Mark Estes III N.A., Marchlinski F.E., et al. Comparing classifications of death in the Mode Selection Trial: agreement and disagreement among site investigators and a clinical events committee. Contemp Clin Trials 27 (2006) 260-268
24. Eisenbud R., Assmann S.F., Kalish L.A., van Der Horst C., and Collier A.C. Differences in difficulty adjudicating clinical events in patients with advanced HIV disease. J Acquir Immune Defic Syndr 28 (2001) 43-46
25. Cleland J.G., Daubert J.C., Erdmann E., Freemantle N., Gras D., Kappenberger L., et al. The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med 352 (2005) 1539-1549
26. Graafsma Y.P., Prins M.H., Lensing A.W., de Haan R.J., Huisman M.V., and Buller H.R. Bleeding classification in clinical trials: observer variability and clinical relevance. Thromb Haemost 78 (1997) 1189-1192
27. Curb J.D., McTiernan A., Heckbert S.R., Kooperberg C., Stanford J., Nevitt M., et al. Outcomes ascertainment and adjudication methods in the Women's Health Initiative. Ann Epidemiol 13 (2003) S122-S128
28. Anderson G.L., Limacher M., Assaf A.R., Bassford T., Beresford S.A., Black H., et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA 291 (2004) 1701-1712
29. Albers G.W., Diener H.C., Frison L., Grind M., Nevinson M., Partridge S., et al. Ximelagatran vs warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: a randomized trial. JAMA 293 (2005) 690-698
30. Halperin J.L. Ximelagatran compared with warfarin for prevention of thromboembolism in patients with nonvalvular atrial fibrillation: Rationale, objectives, and design of a pair of clinical studies and baseline patient characteristics (SPORTIF III and V). Am Heart J 146 (2003) 431-438
31. Soares H.P., Daniels S., Kumar A., Clarke M., Scott C., Swann S., et al. Bad reporting does not mean bad methods for randomised trials: observational study of randomised controlled trials performed by the Radiation Therapy Oncology Group. BMJ 328 (2004) 22-24
32. Eliakim R., Sharma V.K., Yassin K., Adler S.N., Jacob H., Cave D.R., et al. A prospective study of the diagnostic accuracy of PillCam ESO esophageal capsule endoscopy versus conventional upper endoscopy in patients with chronic gastroesophageal reflux diseases. J Clin Gastroenterol 39 (2005) 572-578